Clene Nanomedicine Aims to be the ‘Gold Standard’ in Neurodegenerative Disease

Published on :

Clene Nanomedicine, one of Maryland’s Future 2020 companies, closed a merger with Tottenham Acquisition I Limited that provided the company with a slot on the Nasdaq Exchange and $3.19 million that will be used to advance the company’s gold nanocrystal-based treatment for neurodegenerative diseases.